Q3 2023

Filed Nov 2, 2023 · 10-Q · 33 days after period end · 0000950170-23-058165

Q3 2023 · 10-Q

Revenue

$0.00

no prior Q3 2022 on file

Net Income

-$51.15M

N/M vs Q3 2022

EPS Diluted

-$0.73

N/M vs Q3 2022

Operating Income-$56,355,000N/M

Operating Cash Flow

Same quarter

Metric	Q3 2023	Q3 2022	Q3 2021	Q3 2020
Revenue	$0.00	—	$12.38M	$379.00K
Net Income	-$51.15M	-$35.40M	-$20.64M	-$20.44M
EPS Diluted	-$0.73	-$0.58	-$0.40	-$0.46

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR